Raphael Pharmaceutical (RAPH) Income towards Parent Company (2020 - 2024)
Raphael Pharmaceutical (RAPH) posted Income towards Parent Company of -$1.9 million for Q4 2024, down 505.64% sequentially from -$319000.0 in Q3 2024, and down 70.07% YoY from -$6.5 million in Q1 2024.
Raphael Pharmaceutical (RAPH) Income towards Parent Company (2020 - 2024) Analysis & Trends
Raphael Pharmaceutical has reported Income towards Parent Company for 5 years, with the latest figure at -$1.9 million in Q4 2024.
- Quarterly Income towards Parent Company fell 70.07% year-over-year to -$1.9 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$1.9 million (up 14.17% YoY) and the FY2025 annual result came in at -$3.2 million, down 6.07% from the prior year.
- Income towards Parent Company eased to -$1.9 million in Q4 2024 per RAPH's latest filing, from -$319000.0 in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$175000.0 in Q1 2022 and troughed at -$1.9 million in Q4 2024.
- A 5-year average of -$758235.3 and a median of -$419000.0 in 2023 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2021 and 2024: Income towards Parent Company slumped 371.95% in 2021, then jumped 56.24% in 2024.
- Over 5 years, Income towards Parent Company stood at -$385000.0 in 2020, then tumbled by 371.95% to -$1.8 million in 2021, then retreated by 0.77% to -$1.8 million in 2022, then surged by 37.96% to -$1.1 million in 2023, then sank by 70.07% to -$1.9 million in 2024.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$1.9 million, -$319000.0, and -$249000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.93 Mn |
| Sep 30, 2024 | -319,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -547,000.00 |
| Dec 31, 2023 | -1.14 Mn |
| Sep 30, 2023 | -729,000.00 |
| Jun 30, 2023 | -419,000.00 |
| Mar 31, 2023 | -258,000.00 |
| Dec 31, 2022 | -1.83 Mn |
| Sep 30, 2022 | -1.43 Mn |
| Jun 30, 2022 | -612,000.00 |
| Mar 31, 2022 | -175,000.00 |
| Dec 31, 2021 | -1.82 Mn |
| Sep 30, 2021 | -418,000.00 |
| Jun 30, 2021 | -385,000.00 |
| Mar 31, 2021 | -252,000.00 |
| Dec 31, 2020 | -385,000.00 |